GBS RSI Chart
Last 7 days
-6.4%
Last 30 days
-32.9%
Last 90 days
-12.6%
Trailing 12 Months
-6.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 2.7M | 0 | 0 | 0 |
2023 | 1.2M | 1.4M | 1.9M | 2.3M |
2022 | 2.0M | 2.0M | 748.5K | 927.4K |
2021 | 1.5M | 2.0M | 0 | 2.1M |
2020 | 0 | 188.7K | 636.7K | 1.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Oct 10, 2022 | simeonidis harry | acquired | - | - | 80,000 | president |
Oct 10, 2022 | sakiris spiro kevin | acquired | - | - | 75,000 | chief financial officer |
Oct 10, 2022 | hurd jonathan scott | acquired | - | - | 15,000 | - |
Oct 10, 2022 | boyages steven constantine | acquired | - | - | 75,000 | interim ceo and chairperson |
Oct 10, 2022 | margelis george | acquired | - | - | 15,000 | - |
Oct 10, 2022 | fisher lawrence b | acquired | - | - | 15,000 | - |
Oct 10, 2022 | towers christopher | acquired | - | - | 15,000 | - |
Jun 22, 2022 | sakiris spiro kevin | bought | 3,249 | 0.6498 | 5,000 | chief financial officer |
Jun 17, 2022 | sakiris spiro kevin | bought | 9,765 | 0.6115 | 15,970 | chieffinancial officer |
Feb 17, 2022 | life science biosensor diagnostics pty ltd | sold | -293,774 | 0.51 | -576,028 | - |
Which funds bought or sold GBS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | Headlands Technologies LLC | new | - | 110 | 110 | -% |
May 07, 2024 | CVI Holdings, LLC | new | - | 456,815 | 456,815 | 0.43% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Feb 14, 2024 | CITADEL ADVISORS LLC | new | - | 52,719 | 52,719 | -% |
Feb 14, 2024 | TWO SIGMA INVESTMENTS, LP | new | - | 11,519 | 11,519 | -% |
Feb 14, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 9,948 | 9,948 | -% |
Feb 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | new | - | 50,000 | 50,000 | -% |
Feb 13, 2024 | OMERS ADMINISTRATION Corp | new | - | 14,327 | 14,327 | -% |
Unveiling GBS Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
GBS Inc. News
Income Statement (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Revenue | 7.8% | 823,800 | 764,063 | 796,094 | 287,475 | 457,058 | 356,679 | 311,320 | 66,855 | 192,500 | 177,791 | 1,607,730 | 34,290 | 283,037 | 55,427 | - |
Cost Of Revenue | 14.3% | 645,311 | 564,815 | 563,763 | - | 424,009 | 112,635 | - | - | - | - | - | - | - | - | - |
Gross Profit | -10.4% | 178,489 | 199,248 | 232,331 | - | 33,049 | 244,044 | - | - | - | - | - | - | - | - | - |
Operating Expenses | 37.2% | 3,216,066 | 2,343,809 | 2,868,567 | 2,791,073 | 6,694,128 | 2,644,636 | 1,529,692 | 2,154,948 | 1,535,329 | 3,644,426 | -12,647,556 | 3,174,805 | 1,200,363 | 718,422 | - |
S&GA Expenses | -100.0% | - | 1,705,044 | 2,457,060 | 2,432,242 | 1,898,754 | 2,245,289 | 1,450,418 | 1,462,335 | 1,122,004 | 1,003,244 | 1,153,223 | 1,013,389 | 671,450 | 521,003 | - |
EBITDA Margin | 13.7% | -4.28 | -4.97 | -6.03 | -8.10 | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 18,561 | 81,664 | 85,076 | - |
Earnings Before Taxes | - | - | - | - | - | -6,352,017 | - | - | - | -1,344,133 | -3,463,823 | -850,230 | -3,142,667 | -1,990,389 | -1,076,915 | - |
EBT Margin | 13.7% | -4.72 | -5.47 | -6.64 | -8.92 | -10.57 | -7.65 | -9.48 | -3.47 | -3.53 | -4.23 | -3.56 | - | - | - | - |
Net Income | -51.6% | -2,986,765 | -1,969,641 | -2,432,424 | -2,656,028 | -6,343,906 | -420,600 | -1,214,078 | -2,073,648 | -1,335,246 | -3,463,823 | -847,584 | -3,127,813 | -1,990,389 | -1,076,915 | -1,836,318 |
Net Income Margin | 35.3% | -3.76 | -5.82 | -6.25 | -7.53 | -8.43 | -5.44 | -10.80 | -4.06 | -3.52 | -4.22 | -3.56 | - | - | - | - |
Free Cashflow | 14.7% | -2,446,564 | -2,869,158 | -1,311,833 | -584,338 | -2,518,455 | -2,380,850 | -1,893,735 | -1,723,205 | -292,224 | -1,425,567 | -1,682,811 | - | - | - | - |
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q2 |
Assets | 93.0% | 17,039 | 8,827 | 8,700 | 10,355 | 10,669 | 18,048 | 10,160 | 12,352 | 14,359 | 15,236 | 19,107 | 21,859 | 17,453 | 19,966 | 2,476 |
Current Assets | 291.2% | 11,521 | 2,945 | 2,692 | 3,863 | 4,423 | 6,378 | 8,207 | 10,868 | 12,865 | 14,085 | 15,860 | 18,207 | 16,586 | 19,966 | 2,340 |
Cash Equivalents | 739.8% | 9,398 | 1,119 | 186 | 1,537 | 2,281 | 2,912 | 5,743 | 8,238 | 10,756 | 11,191 | 12,608 | 12,574 | 14,262 | 19,878 | 427 |
Inventory | -6.8% | 878 | 942 | 965 | 980 | 736 | 671 | - | - | - | - | - | - | - | - | - |
Net PPE | -5.4% | 560 | 591 | 665 | 690 | 478 | 484 | 416 | 391 | - | - | - | - | - | - | - |
Goodwill | - | - | - | - | - | - | 4,130 | 3,803 | - | - | - | - | - | - | - | - |
Liabilities | 6.5% | 6,041 | 5,673 | 7,464 | 6,668 | 4,742 | 7,785 | 4,964 | 5,806 | 5,656 | 5,191 | 5,606 | 6,853 | 1,577 | 1,184 | 7,690 |
Current Liabilities | 10.1% | 5,706 | 5,183 | 6,846 | 5,884 | 3,536 | 4,815 | 2,357 | 4,663 | 4,432 | 4,009 | 2,833 | 3,683 | 1,559 | 1,166 | 7,690 |
Shareholder's Equity | 235.3% | 10,998 | 3,280 | 1,237 | 3,799 | 6,026 | 10,263 | 5,196 | 6,546 | 8,703 | 10,045 | 13,501 | 15,007 | 15,875 | 18,782 | - |
Retained Earnings | -6.4% | -49,180 | -46,202 | -44,232 | -41,807 | -39,148 | -32,804 | -32,384 | -31,175 | -29,097 | -27,762 | -24,302 | -22,869 | -22,016 | -18,888 | -15,832 |
Additional Paid-In Capital | 21.9% | 60,946 | 49,986 | 46,159 | 46,180 | 45,773 | 43,687 | 38,440 | 38,581 | 38,440 | 38,440 | 38,440 | 38,440 | 38,440 | 37,957 | 10,900 |
Shares Outstanding | 97.4% | 2,914 | 1,476 | 2,330 | 194 | 1,685 | 918 | 14,890 | - | 730 | - | 14,006 | 10,415 | - | - | - |
Minority Interest | -7.2% | -135 | -125 | -119 | -111 | -99.52 | -91.41 | -84.94 | -79.15 | -69.13 | -60.24 | -56.41 | -51.23 | -53.99 | -39.14 | -28.31 |
Float | - | - | - | - | - | - | 3,665 | - | 9,857 | - | 17,349 | - | - | - | 35,140 | - |
Cashflow (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | 14.7% | -2,446 | -2,869 | -1,311 | -584 | -2,518 | -2,380 | -1,893 | -1,723 | -292 | -1,425 | 83.00 | -1,682 | -6,159 | -776 | -2,677 | - | - | - |
Share Based Compensation | - | 218 | - | - | - | - | 260 | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Investing | - | 3.00 | - | - | -181 | 174 | -211 | -474 | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | - | 10,769 | - | - | 46.00 | 1,718 | - | - | - | - | - | - | - | 498 | 19,610 | 3,295 | - | - | - |
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||||
---|---|---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |||
Income Statement [Abstract] | ||||||
Revenue | $ 764,063 | $ 356,679 | $ 1,560,157 | $ 356,679 | ||
Cost of revenue (exclusive of amortization shown separately below) | (564,815) | (112,635) | (1,128,578) | (112,635) | ||
Gross profit | 199,248 | 244,044 | 431,579 | 244,044 | ||
Other income: | ||||||
Government support income | 153,204 | 269,625 | 263,075 | 580,945 | ||
Operating expenses: | ||||||
Selling, general and administrative expenses | (1,705,044) | (2,245,289) | (4,162,104) | (3,695,707) | ||
Development and regulatory approval expenses | (348,452) | (1,191) | (452,399) | (80,465) | ||
Depreciation and amortization | (290,313) | (398,156) | (597,873) | (398,156) | ||
Total operating expenses | (2,343,809) | (2,644,636) | (5,212,376) | (4,174,328) | ||
Loss from operations | (1,991,357) | (2,130,967) | (4,517,722) | (3,349,339) | ||
Other income (expense): | ||||||
Interest expense | (32,468) | (76,767) | (69,916) | (77,832) | ||
Realized foreign exchange loss | (555) | (13,901) | (555) | (16,148) | ||
Fair value gain on revaluation of financial instrument | 44,488 | 1,793,091 | 175,738 | 1,793,091 | ||
Interest income | 3,509 | 1,473 | 3,648 | 9,079 | ||
Total other income | 14,974 | 1,703,896 | 108,915 | 1,708,190 | ||
Net loss | (1,976,383) | (427,071) | (4,408,807) | (1,641,149) | ||
Net loss attributable to non-controlling interest | (6,742) | (6,471) | (13,962) | (12,256) | ||
Net loss attributable to Intelligent Bio Solutions Inc. | (1,969,641) | (420,600) | (4,394,845) | (1,628,893) | ||
Other comprehensive income, net of tax: | ||||||
Foreign currency translation gain | 75,133 | 361,597 | 57,117 | 226,038 | ||
Total other comprehensive income | 75,133 | 361,597 | 57,117 | 226,038 | ||
Comprehensive loss | (1,901,250) | (65,474) | (4,351,690) | (1,415,111) | ||
Comprehensive loss attributable to non-controlling interest | (6,742) | (6,471) | (13,962) | (12,256) | ||
Comprehensive loss attributable to Intelligent Bio Solutions Inc. | $ (1,894,508) | $ (59,003) | $ (4,337,728) | $ (1,402,855) | ||
Net loss per share, basic | [1] | $ (2.07) | $ (5.56) | $ (7.68) | $ (23.65) | |
Net loss per share, diluted | [1] | $ (2.07) | $ (5.56) | $ (7.68) | $ (23.65) | |
Weighted average shares outstanding, basic | [1] | 949,660 | 75,690 | 571,930 | 68,866 | |
Weighted average shares outstanding, diluted | [1] | 949,660 | 75,690 | 571,930 | 68,866 | |
|
Condensed Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Jun. 30, 2023 | ||
---|---|---|---|---|
Current assets: | ||||
Cash and cash equivalents | $ 1,119,004 | $ 1,537,244 | ||
Accounts receivable, net | 262,834 | 293,861 | ||
Inventories, net | 942,050 | 979,907 | ||
Research and development tax incentive receivable | 289,167 | 498,758 | ||
Other current assets | 331,601 | 552,791 | ||
Total current assets | 2,944,656 | 3,862,561 | ||
Property and equipment, net | 591,307 | 690,175 | ||
Operating lease right-of-use assets | 432,728 | 546,475 | ||
Intangible assets, net | 4,858,301 | 5,255,401 | ||
TOTAL ASSETS | 8,826,992 | 10,354,612 | ||
Current liabilities: | ||||
Accounts payable and accrued expenses | 1,763,007 | 2,610,028 | ||
Current portion of operating lease liabilities | 250,751 | 223,447 | ||
Current portion of deferred grant income | 2,431,900 | 2,338,057 | ||
Current employee benefit liabilities | 366,893 | 358,942 | ||
Current portion of notes payable | 370,535 | 353,211 | ||
Total current liabilities | 5,183,086 | 5,883,685 | ||
Employee benefit liabilities, less current portion | 29,993 | 24,902 | ||
Operating lease liabilities, less current portion | 228,710 | 356,165 | ||
Notes payable, less current portion | 230,969 | 402,862 | ||
Total liabilities | 5,672,758 | 6,667,614 | ||
Shareholders’ equity: | ||||
Common stock, $0.01 par value, 100,000,000 shares authorized, 1,476,042 and 194,200 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively | [1] | 14,760 | 1,942 | |
Treasury stock, at cost, 116 shares as of December 31, 2023 and June 30, 2023, respectively | [1] | (1) | (1) | |
Additional paid-in capital | 49,986,220 | 46,180,112 | ||
Accumulated deficit | (46,202,418) | (41,807,573) | ||
Accumulated other comprehensive loss | (518,379) | (575,496) | ||
Total consolidated Intelligent Bio Solutions Inc. equity | 3,280,182 | 3,798,984 | ||
Non-controlling interest | (125,948) | (111,986) | ||
Total shareholders’ equity | 3,154,234 | 3,686,998 | ||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ 8,826,992 | $ 10,354,612 | ||
|